ERK and RAF Inhibitor Combination for Resistant MAPK-Driven Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments targeting the MAPK signaling pathway, such as BRAF and MEK inhibitors, exhibit variable efficacy due to genetic heterogeneity and drug resistance, necessitating novel agents that can inhibit diverse oncogenic pathways and overcome adaptive resistance.
Innovation Solution
Combining BVD-523, an ERK inhibitor, with TAK-632, a second anti-cancer agent, to achieve a synergistic effect in treating cancer by targeting multiple nodes of the MAPK pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BRAF and MEK inhibitors are used to treat cancer, then cancer cell growth is inhibited, but variable efficacy is observed due to genetic heterogeneity and drug resistance
Solution Approach 1:
The patent segments the MAPK pathway into multiple target nodes (BRAF, MEK, ERK) and employs inhibitors at each segment. By using combination therapy targeting multiple pathway components simultaneously, the treatment addresses genetic heterogeneity and prevents adaptive resistance that occurs with single-node inhibition.
Solution Approach 2:
The patent employs composite therapeutic strategies by combining multiple inhibitors (BRAF inhibitor, MEK inhibitor, and ERK inhibitor) into a unified treatment regimen. This composite approach creates synergistic effects that enhance overall treatment efficacy and overcome the adaptability challenges of cancer cells with diverse genetic profiles.
2Ease of operation
If single-agent therapy is used, then treatment simplicity is maintained, but disease progression occurs due to acquired drug resistance
Solution Approach 1:
The patent merges multiple inhibitors (BRAF, MEK, and ERK inhibitors) into a combination therapy regimen. This merging of therapeutic agents creates synergistic effects that extend the duration of response by simultaneously targeting multiple pathway nodes, thereby preventing acquired resistance while maintaining manageable treatment protocols.
Solution Approach 2:
The patent employs preliminary action by pre-establishing combination therapy that targets multiple pathway nodes before resistance can develop. By inhibiting ERK activity alongside BRAF and MEK inhibition, the treatment preemptively blocks adaptive pathways that would otherwise enable cancer cells to survive and progress despite initial treatment success.
3Reliability
If combination therapy targeting multiple pathway nodes is used, then synergistic effect is achieved, but treatment complexity increases
Solution Approach 1:
The patent applies local quality by selectively targeting specific pathway nodes (BRAF, MEK, ERK) with appropriate inhibitors based on the cancer's genetic profile and pathway activation status. This localized approach to pathway inhibition maximizes synergistic effects at critical nodes while avoiding unnecessary complexity in targeting non-relevant pathway components.
Data Source
Figure 1A~1B
Figure 1C
Figure 2A
AI summary
The present invention provides, inter alia, methods of treating or ameliorating the effects of a cancer in a subject. The methods include administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 1 RAF inhibitor (such as dabrafenib) or another RAF inhibitor (such as regorafenib) or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Also provided are pharmaceutical compositions and kits for treating or ameliorating the effects of a cancer in a subject.